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NEW ALTERNATIVE CORONARY BYPASS GRAFT: FIRST CLINICAL EXPERIENCE WITH AN 
AUTOLOGOUS ENDOTHELIALIZED CRYOPRESERVED ALLOGRAFT
Peter Lamm, MD,a Gerd Juchem, MD,b Peter Weyrich,c Stephan Nees, MD,c and Bruno Reichart, MD,a Munich, Germany
A 72-year-old woman with unstable angina and dyspnea
came to our department in October 1997 for evaluation of the
possibility of an aorta-coronary bypass operation. Coronary
angiography showed severe 3-vessel disease combined with
significant left main coronary artery stenosis. In the ventricu-
logram the posterior wall of both ventricles was seen to be
akinetic as the result of a previous myocardial infarction.
There was evidence of a significant mitral insufficiency. The
ejection fraction was 0.45. Cardiopulmonary resuscitation
was needed several times, the most recent occasion being in
November 1997. In addition the patient had hypertension and
insulin-dependent diabetes mellitus, resulting in diabetic kid-
ney failure and peripheral polyneuropathy. The patient had
previously had 2 strokes, leading to the paraparesis of both
legs, and as a result required a wheelchair. Femoral-popliteal
reconstructions were done on both legs, with early graft
thrombosis. In addition this patient was a known carrier of
factor V Leiden mutation.
Initially the lack of sufficient bypass material prevented an
operation. The veins of both legs had been used previously
for peripheral revascularization. Because of the possibility of
infection and instability of the sternum, the combined use of
left and right internal thoracic arteries was regarded as being
too risky. The use of a wheelchair prevented the use of the
radial arteries. Because of the resistant and intractable angi-
na, we decided to perform the revascularization with an autol-
ogous endothelialized cryopreserved vein allograft. It was
possible to harvest a 4-cm long vein remnant from the right
leg and isolate human saphenous vein endothelial cells.
Cultivation was done by regular cell tissue techniques. Once
a sufficient number of human saphenous vein endothelial
cells (approximately 5 · 106 cells) was available, an ABO-
compatible cryopreserved vein allograft was thawed rapidly
in water at 37°C. For the total removal of the native human
saphenous vein endothelial cells, a Fogarty catheter was rig-
orously pulled through the vein in the direction of the origi-
nal blood flow to prevent damage to the venous valves. The
vein was then filled with the patient’s autologous serum and
placed in an incubator at 37°C for approximately 12 hours.
Subsequently vein endothelialization was initiated by seeding
1.2 · 105 human saphenous vein endothelial cells/cm2 inner
graft surface in a rotating device (3 hours, 37°C, .25 rpm).
After homogeneous adhesion of the human saphenous vein
endothelial cells to the inner graft surface had been achieved,
the vein was placed in a special cultivation apparatus (Fig 1).
After 7 days of cultivation the implantation of this graft on
the circumflex artery was performed on January 14, 1998,
with the written informed consent of the patient. The left
anterior descending artery was bypassed with the left internal
thoracic artery. The operation took place without complica-
tions. Intraoperative flow measurements of the vein allograft
documented a flow of 90 mL/min. Scanning electron micro-
scopic evaluation of preoperatively and intraoperatively col-
lected samples of the vein wall showed an intact endothelium
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(Fig 2). Thirteen hours after the operation the patient was
extubated and 4 days later she was referred to the regular
ward. Postoperative hemodynamics and ultrasonographic car-
diography demonstrated increased myocardial function. On
examination 181 days later, the bypass was determined angio-
graphically to be open and nondilated (Fig 3). Since the oper-
ation the patient has not had recurrence of angina.
Immunosuppressive agents were not administered.
Discussion. Cryopreserved vein allografts have been used
in treatment of patients without sufficient autologous graft
material.1-4 The lack of vascular endothelium has generally
been considered to be responsible for early graft failure.1,4
Autologous endothelialization5 of cryopreserved vein allo-
graft may be the long sought answer, providing a new and
reliable source of bypass material with long-term patency. In
a current research project at our clinic we developed a simple,
reliable, and reproducible method of endothelializing cryo-
preserved vein allografts with the patient’s autologous
endothelial cells. The production period of these endothelial-
ized grafts is about 3 weeks. Histologic studies of these grafts
after perfusion have shown a stable and intact endothelium
that cannot be distinguished from regular endothelium.
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Fig 1. Endothelialization of venous allograft. Vein (1), in which autologous endothelial cells have already been
seeded, is maintained in medium-filled cultivation vessel (2). Ends of vein are attached to vessel outlets with
adapters (3). Distal vessel end is attached to medium-filled Boyle-Marriot bottle (4). Proximal end leads to waste-
collection vessel (5). Both ends include sterile filters (6) and 3-way taps (7). Pressure gradient (D P), which
depends on depth of cannula (8), is chosen to just prevent collapse of vein. Medium in vein lumen is exchanged
daily by computer-controlled pump (9).
Fig 2. Scanning electron micrograph of interior surface of
vein after successful continuous re-endothelialization of
entire inner surface with autologous saphenous vein endothe-
lial cells (sample taken immediately before central anasto-
mosis of vein graft). (Original magnification 30· .). Inset is at
higher magnification. (Original magnification 100· .)
Fig 3. Coronary arteriogram of autologous endothelialized
venous coronary artery bypass 181 days after operation.
Arteriogram shows patent, nondilated allograft.
The case presented here demonstrates that the use of autol-
ogous endothelialized cryopreserved allograft veins may
make bypass procedures available even to those patients
whose disease to date has been considered inoperable because
of a lack of bypass material. The easy handling of such veins
and the simplicity of the coating procedure should be a con-
siderable step forward in cardiovascular surgery. We are cur-
rently selecting new candidates with apparently inoperable
disease for further clinical application of this new technique.
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